RevMed pads Rasonque’s first-line survival advantage in pancreatic cancer with early data
The new data could help boost Revolution Medicines beyond the currently estimated $14.5 billion in peak sales for the recently approved RAS(ON) inhibitor, Truist Securities predicts.
comments(0)
5-min edit window · permanent after that